EP
NVCR icon

Edgestream Partners’s NovoCure NVCR Stock Holding History

Edgestream Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-208,329
Closed -$3.71M – 1002
2025
Q2 		$3.71M Buy
208,329
+48,057
+30% +$837K 0.1% 375
2025
Q1 		$2.86M Buy
+160,272
New +$3.64M 0.1% 388
2024
Q4 		– Sell
-115,929
Closed -$1.81M – 1020
2024
Q3 		$1.81M Buy
+115,929
New +$2.1M 0.08% 433
2024
Q1 		– Sell
-105,899
Closed -$1.58M – 963
2023
Q4 		$1.58M Buy
+105,899
New +$1.42M 0.11% 300
2023
Q1 		– Sell
-34,635
Closed -$2.54M – 622
2022
Q4 		$2.54M Buy
34,635
+20,477
+145% +$1.54M 0.29% 103
2022
Q3 		$1.08M Buy
+14,158
New +$1.1M 0.08% 267

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Edgestream Partners's NVCR Position: Q3 2025 in Review

Edgestream Partners sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 208,329 shares — an estimated $3.71M sold.

Edgestream Partners first reported a position in NVCR in Q3 2022 and held it in 6 quarters. The position peaked at $3.71M in Q2 2025. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Edgestream Partners reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
  • Edgestream Partners sold 208,329 NovoCure shares in Q3 2025, an estimated $3.71M.
  • Edgestream Partners first reported a position in NovoCure in Q3 2022 and held it in 6 quarters.
  • Edgestream Partners's NovoCure position peaked at $3.71M in Q2 2025.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Edgestream Partners's 13F filing for Q3 2025, filed 12 Nov 2025.